APOH and autoimmune polyendocrinopathy: Nevertheless, it has been suggested by Gropp et al [202] that eculizumab may act by blocking the pro-complement activity of the aβ2GPI/β2GPI complex and thus compensating for the dysregulation of β2GPI-complement interactions in APS.